Secukinumab Use in Refractory Giant Cell Arteritis In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/HkMT9QEMg8

Management of SLE: -Treat early to prevent organ damage -Taper GC to <5mg/d in the first 6m when feasible -New therapies are promising but still unmet needs in LN, limited global access and lacking data in pregnancy. #EULAR2025 @RheumNow https://t.co/UKK8sTYJD2

• https://x.com/AdelaCastro222/status/1932350268102091208/photo/1
• https://x.com/AdelaCastro222/status/1932350268102091208/photo/1

#EULAR2025 Abstr#OP0035 SGLT2-i and GLP-1 agonist are increasingly used to treat diabetes. Population based study in Canada showed no significant difference in risk of developing an autoimmune rheumatic disease with GLP-1-RA or SGLT2i relative to DPP4i treatment @RheumNow https://t.co/CvPcOqehtl

• https://x.com/Yuz6Yusof/status/1932939395834818772/photo/1

+RCT in #pSjD #Sjogrens #Disease #Leflunomide + #hydroxychloroquine Vs #PBO 2nd study to show this - same group need to know ▶️what pt to use this in ▶️is there diff organ improvements ⬆️#ESSDAI ⬇️RF ⬇️Ig’s Easy to prescribe ?early, mild dx #EULAR2025 @RheumNow @eular_org https://t.co/JE0VyFRXc6

• https://x.com/Janetbirdope/status/1933873925429383674/photo/1
• https://x.com/Janetbirdope/status/1933873925429383674/photo/1
• https://x.com/Janetbirdope/status/1933873925429383674/photo/1
• https://x.com/Janetbirdope/status/1933873925429383674/photo/1

#EULAR2025 Based on the updated EULAR Guidelines on #lupus nephritis, should all patients receive early Combination therapies for remission induction? @RheumNow

In BIODOPT study (RA, PsA, axSpA), disease activity-guided tapering of biologics (incl. biosimilars) maintained QALY (Δ0.008, NS) while lowering biologic costs (Δ€–1,979 [95%CI –3,798;–161]) & total hospital costs (Δ€–1,936 [95%CI –3,753;–119]) over 18mo. Supports https://t.co/CJUpfU2oRA

• https://x.com/synovialjoints/status/1933900613902893138/photo/1

ARIAA study: longer-term data now High-risk ACPA+ clinically suspect arthralgias abatacept for 6mo, then stop altogether Really impressive long-term effect also noting success of APIPPRA, abatacept flicks off some very early RA, at least for a while #EULAR2025 OP0325 @RheumNow https://t.co/AeRrUKPPiK https://t.co/jtynyD0ioO

• https://x.com/drdavidliew/status/1933612907033452725/photo/1
• https://twitter.com/drdavidliew/status/1533099103114211328

EULAR FMF recommendations 2025: still emphasis on colchicine adherence to maximal dose +/- bDMARDs if needed for control +/- csDMARDs for residual chronic MSK involvement new: consider tapering bDMARD if remission >6mo See the treatment algorithm below⬇️ #EULAR2025 @RheumNow https://t.co/Hy6DOKzfUL

• https://x.com/drdavidliew/status/1933786027857998292/photo/1
• https://x.com/drdavidliew/status/1933786027857998292/photo/1

FMF #Recommendations 🔺️Start Colchicine in All (& continue for confirmed pts) 🔺️Single or divided dose, depend on adherence & tolerance 🔺️Max dose 2 mg children, 3 mg adults 🔺️if failure: add IL1i (6 RCT) (2 for IL6i) 🔺️Add c or bDMARd if MSK #EULAR2025 @RheumNow https://t.co/fPyQrLbb6S

• https://x.com/Nellziade/status/1933787923419189744/photo/1

FMF #Recommendations During attack: 🔺️No use of increasing Colchicine 🔺️No use for corticosteroids and opioid 🔺️Use NSAIDs #EULAR2025 @RheumNow https://t.co/jJjWJra7yr

• https://x.com/Nellziade/status/1933787923851457020/photo/1

FMF #Recommendations #Colchicine can be fatal 🔺️Monitor regularly #EULAR2025 @RheumNow https://t.co/VJZYPaBrvE

• https://x.com/Nellziade/status/1933789626692509988/photo/1

FMF #Recommendations #Colchicine can be fatal 🔺️Beware of drug interactions 🔺️Mostly statins in adults 🔺️Macrolides in children #EULAR2025 @RheumNow https://t.co/SYGLpAJXFu

• https://x.com/Nellziade/status/1933794041214148656/photo/1

“That is why this task force continues to say: nothing is better than methotrexate and glucocorticoids to start” - Josef Smolen, on RA treatment #EULAR2025 @RheumNow https://t.co/AbkgWS8tvH

• https://x.com/drdavidliew/status/1933800591379099779/photo/1
• https://x.com/drdavidliew/status/1933800591379099779/photo/1

The key changes for the new 2025 EULAR recommendations on RA treatment #EULAR2025 @RheumNow https://t.co/dp5LnoFdpW

• https://x.com/drdavidliew/status/1933801766572728598/photo/1

URAT1 inhibitors look like the way to go in Gout! Presented in multiple abstracts at #EULAR2025 Pozdeutinurad Ph2 long term safety data chronic gouty arthritis + tophi OP0300 Ph3 RCT of Ruzinurad in hyperuricemia/primary gout OP0302 Ph 2b RCT of SAP-001 Refractory Gout +/-